<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1672">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02147600</url>
  </required_header>
  <id_info>
    <org_study_id>EC UZG 2013/1148</org_study_id>
    <nct_id>NCT02147600</nct_id>
  </id_info>
  <brief_title>Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients</brief_title>
  <official_title>Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to determine optimal cut-off values of adalimumab trough
      levels corresponding to good clinical response. Determination of these values is necessary
      to compose a therapeutic algorithm, in which the dosing schedule can be adjusted according
      to serum trough levels of adalimumab and AAA (anti-adalimumab antibodies). A secondary
      objective of this study is to further detect and quantify AAA and to correlate them with
      adalimumab and clinical response in a real life setting cohort of psoriatic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a multicenter cross-sectional study, 73 adult patients treated with adalimumab (40 mg)
      every other week for at least 24 weeks are assessed for psoriasis disease severity through
      measurement of the Psoriasis Area and Severity Index (PASI) before adalimumab treatment
      start, and prior to sampling. Patients who interrupted their treatment schedule during the
      24 weeks prior to blood sampling are excluded. Samples of patients who were treated with
      adalimumab for any other inflammatory disease and later developed psoriasis are also
      excluded. Percentage of PASI improvement compared to baseline (∆PASI) represents clinical
      response. Patients are classified as nonresponders (∆PASI&lt;50), moderate responders (∆PASI
      50-75) or good responders (∆PASI 75-100).Serum is collected for adalimumab trough level and
      anti-drug antibody determination (Sanquin, The Netherlands). By receiver-operator
      characteristics (ROC) analysis, a cut-off value of adalimumab trough level can be determined
      to distinguish insufficient from adequate responders.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>75% improvement in clinical response</measure>
    <time_frame>at least 24 weeks of treatment duration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minimum of 75 % PASI improvement compared to baseline (∆PASI 75) represents 75% improvement in clinical response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>anti-adalimumab antibody formation</measure>
    <time_frame>at least 24 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Chronic plaque psoriasis</arm_group_label>
    <description>Patients suffering from chronic plaque psoriasis, treated with adalimumab (40mg) subcutaneously every other week after an initial dose of 80 mg. Treatment duration of at least 24 weeks.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  Primary care clinic

          -  University Hospital

          -  Private dermatology practice
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  minimum age 18 years old

          -  chronic plaque psoriasis

          -  adalimumab (40mg) subcutaneously every other week

          -  at least 24 weeks of adalimumab treatment

        Exclusion Criteria:

          -  interruption of treatment schedule during 24 weeks prior to sampling

          -  adalimumab for other inflammatory disease and later developed psoriasis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jo Lambert, Prof.Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Ghent University, Dpt. of Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emma Coussens</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ghent University, Dpt. of Dermatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emma Coussens</last_name>
    <phone>0032 473402559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Ghent University, Dpt. of Dermatology</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coussens</last_name>
      <email>emma.coussens@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Emma Coussens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maria Middelares Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L. Temmerman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Lucas Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L. Dierckxsens</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H Hart Hospital</name>
      <address>
        <city>Mol</city>
        <zip>2400</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. Boonen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ST Rembert Hospital</name>
      <address>
        <city>Torhout</city>
        <zip>8820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Stockman</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adalimumab</keyword>
  <keyword>biologicals</keyword>
  <keyword>immunogenicity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
